depression

Johnson & Johnson’s Ketamine-Based Drug Treats Depression

SO THEY SAY –

July 22, 2024 – Close to 30 percent of the estimated 280 million people in the world living with major depressive disorder have treatment resistant depression. Sales of Spravato soared 60% to $271 million in the three months ended June 30, compared with the same period in 2023. Spravato has been used by 100,000 people in 77 countries, according to Johnson & Johnson. Spravato is administered as nasal spray and must be taken under the supervision of a healthcare provider in a healthcare setting. Unlike, other antidepressants that regulate chemicals like serotonin and dopamine in the brain, Spravato works by boosting glutamate in the brain. Glutamate is the most abundant neurotransmitter in the brain and helps neurons communicate with each other. 

CONTINUE@Quartz

C Luke

Recent Posts

Where does that leave marijuana?

TIME WILL TELL – Nov. 11, 2024 - President-elect Donald Trump is expected to come…

2 days ago

Cannabis Use Linked to Epigenetic Changes – Cancer Risk

POT IS SO OBSOLETE – Nov. 15, 2024 -  Cannabis is a “genotoxic” substance because…

2 days ago

Vending Machines Offer Clean Free Needles and Narcan

NPR AUDIO – STICK WITH THE WINNERS!  – Nov. 14, 2024 - “I don’t shoot…

2 days ago

This Book Will Save Your Life: The New Medical Cure for Opioid Addiction

NEW BOOK! READING MATTERS – Nov. 15, 2024 - “This is a pointed and urgent…

2 days ago

15 Incredible Films With Gut-Wrenchingly Depictions of Alcoholism

DON’T MISS THESE – 2023 - 1. “Barfly” (1987) Directed by Barbet Schroeder and based…

2 days ago

My Mom Said 1 Word On Her Deathbed That Made Me Look At My Life In A Different Way

NOT WHAT YOU THINK – Nov. 9, 2024 - She reached out her other hand…

2 days ago